This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stearns, J. D. Articles by Hogue, C. W. Search for Related Content PubMed PubMed Citation Articles by Stearns, J. D. Articles by Hogue, C. W., Jr Related Collections Cardiovascular Complications Preoperative Evaluation Outcomes Patient Safety

---

CARDIOVASCULAR ANESTHESIOLOGY

Prognostic Value of Troponin I Levels for Predicting Adverse Cardiovascular Outcomes in Postmenopausal Women Undergoing Cardiac Surgery

Joshua D. Stearns, MD^*, Victor G. Dávila-Román, MD, Benico Barzilai, MD, Richard E. Thompson, PhD, Kelly L. Grogan, MD^*, Betsy Thomas, RN, and Charles W. Hogue, Jr, MD^*

From the *Department of Anesthesiology and Critical Care Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland; Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri; Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; and Department of Clinical Research, Washington University School of Medicine, St. Louis, Missouri.

Address correspondence to Charles W. Hogue, Jr., MD, Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins Hospital, 600 N. Wolfe St., Tower 711, Baltimore, MD 21287. Address e-mail to chogue2{at}jhmi.edu.

Abstract

BACKGROUND: Adverse cardiac events that follow cardiac surgery are an important source of perioperative morbidity and mortality for women. Troponin I provides a sensitive measure of cardiac injury, but the levels after cardiac surgery may vary between sexes. Our purpose in this study was to evaluate the prognostic value of troponin I levels for predicting cardiovascular complications in postmenopausal women undergoing cardiac surgery.

METHODS: The cohort of this study were women enrolled in a previously reported clinical trial evaluating the neuroprotective potential of 17β-estradiol in elderly women. In that study, 175 postmenopausal women not receiving estrogen replacement therapy and scheduled to undergo coronary artery bypass graft (with or without valve surgery) were prospectively randomized to receive 17β-estradiol or placebo in a double-blind manner beginning the day before surgery and continuing for 5 days postoperatively. Serial 12-lead electrocardiograms were performed and serum troponin I concentrations were measured before surgery, after surgery on arrival in the intensive care unit, and for the first four postoperative days. The primary end-point of the present study was major adverse cardiovascular events (MACE) defined as a Q-wave myocardial infarction, low cardiac output state or death within 30 days of surgery. The diagnosis of Q-wave myocardial infarction was made independently by two physicians blinded to treatment and patient outcomes with the final diagnosis requiring consensus. Low cardiac output state was defined as cardiac index <2.0 L · min^–1 · m^–2 for >8 h regardless of treatment.

RESULTS: Troponin I levels on postoperative day 1 were predictive of MACE (area under the receiver operator curve = 0.862). A cutoff point for troponin I of >7.6 ng/mL (95% confidence interval, 6.4–10.8) provided the optimal sensitivity and specificity for identifying patients at risk for MACE. The negative predictive value of a troponin I level for identifying a patient with a composite cardiovascular outcome was high (96%) and the positive predictive value moderate (40%). Postoperative troponin I levels were not different between women receiving perioperative 17β-estradiol treatment compared with placebo and the frequency of MACE was not influenced by 17β-estradiol treatment.

CONCLUSIONS: In postmenopausal women, elevated troponin I levels on postoperative day 1 are predictive of MACE. Monitoring of perioperative troponin I levels might provide a means for stratifying patients at risk for adverse cardiovascular events.

This article has been cited by other articles:

				A. H. B. Wu Gender-Specific Decision Limits for Cardiac Troponin for Risk Stratification? Anesth. Analg., March 1, 2009; 108(3): 686 - 688. [Full Text] [PDF]